Review





Similar Products

foxp3 fixation permeabilization kit  (Fisher Scientific)
86
Fisher Scientific foxp3 fixation permeabilization kit
Foxp3 Fixation Permeabilization Kit, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/buffer+factor+foxp3+set+staining+transcription/bio_rxiv__64898__2026__03__23__713589-306-8-11
Average 86 stars, based on 1 article reviews
foxp3 fixation permeabilization kit - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
foxp3 transcription factor fixation permeabilization buffer  (Cytek Biosciences)
97
Cytek Biosciences foxp3 transcription factor fixation permeabilization buffer
Foxp3 Transcription Factor Fixation Permeabilization Buffer, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/Foxp3+%2F+Transcription+Factor+Staining+Buffer+Kit/pm41467787-420-19-23
Average 97 stars, based on 1 article reviews
foxp3 transcription factor fixation permeabilization buffer - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
foxp3 fixation permeabilization buffer  (Thermo Fisher)
99
Thermo Fisher foxp3 fixation permeabilization buffer
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation Permeabilization Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/Sucrose/bio_rxiv__2025__10__27__684825-348-14-17
Average 99 stars, based on 1 article reviews
foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
fixation permeabilization solution  (Cytek Biosciences)
97
Cytek Biosciences fixation permeabilization solution
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Fixation Permeabilization Solution, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/Foxp3+%2F+Transcription+Factor+Staining+Buffer+Kit/bio_rxiv__2025__10__25__684515-300-11-13
Average 97 stars, based on 1 article reviews
fixation permeabilization solution - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
ebiosciencetm foxp3 fixation permeabilization buffer  (Novus Biologicals)
95
Novus Biologicals ebiosciencetm foxp3 fixation permeabilization buffer
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Ebiosciencetm Foxp3 Fixation Permeabilization Buffer, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/FoxP3/pmc12701028-65-7-27
Average 95 stars, based on 1 article reviews
ebiosciencetm foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
fc foxp3 transcription factor fixation permeabilization concentrate  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc fc foxp3 transcription factor fixation permeabilization concentrate
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Fc Foxp3 Transcription Factor Fixation Permeabilization Concentrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/FoxP3%2FTranscription+Factor+Fixation%2FPermeabilization+Concentrate/10__1016_slash_j__jpet__2025__103744-463-141-163
Average 93 stars, based on 1 article reviews
fc foxp3 transcription factor fixation permeabilization concentrate - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
foxp3 transcription factor fixation permeabilization concentrate  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc foxp3 transcription factor fixation permeabilization concentrate
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Transcription Factor Fixation Permeabilization Concentrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/FoxP3%2FTranscription+Factor+Fixation%2FPermeabilization+Concentrate/pm41005293-799-92-119
Average 93 stars, based on 1 article reviews
foxp3 transcription factor fixation permeabilization concentrate - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
fixation permeabilization kit  (Elabscience Biotechnology)
94
Elabscience Biotechnology fixation permeabilization kit
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Fixation Permeabilization Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxp3+fixation/Foxp3%2FTranscription+Factor+Staining+Kit/10__7150_slash_ijbs__116740-348-5-8
Average 94 stars, based on 1 article reviews
fixation permeabilization kit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

Image Search Results


a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

Journal: bioRxiv

Article Title: Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells

doi: 10.1101/2025.10.27.684825

Figure Lengend Snippet: a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

Article Snippet: Subsequently, extracellular master mix, prepared with the antibodies listed in Table S6 diluted in Foxp3 Fixation/Permeabilization Buffer (Invitrogen, 00-5523-00), was added and samples were incubated for 30 min at 4°C.

Techniques: Flow Cytometry, Mutagenesis